Editorial: Safety and tolerability of rifaximin for IBS - More information is required; Authors' reply

摘要

We appreciate the comments of Cai and Yang, but we respectfully disagree with several of their criticisms. First, this study was not a systematic review. It is a pooled analysis of individual patient data and data on safety for each dose of medication are provided. Nevertheless, there is no difference in safety or tolerability regardless of dose. This is unsurprising as less than 1% of rifaximin is absorbed.